Rescue of Recombinant Newcastle Disease Virus from cDNA
October 11th, 2013
19.9K views
Newcastle disease virus (NDV) has been extensively studied in the last few years in order to develop new vectors for vaccination and therapy, among others. These studies have been possible due to techniques to rescue recombinant virus from cDNA, such as those we describe here.
Overview
This article describes a procedure to rescue recombinant Newcastle disease virus (NDV) from cloned DNA. The method involves infecting mammalian cells with a helper virus and transfecting them with plasmids for virus replication.
Key Study Components
Area of Science
- Virology
- Vaccine Development
- Gene Therapy
Background
- Newcastle disease virus (NDV) is a significant pathogen in avian species.
- Recent studies focus on developing NDV as a vector for vaccines and therapies.
- Rescue of recombinant viruses from cDNA is crucial for these applications.
- Techniques for NDV rescue have advanced significantly in recent years.
Purpose of Study
- To provide a detailed methodology for rescuing NDV from cloned DNA.
- To facilitate the development of NDV-based vectors for therapeutic use.
- To enhance understanding of NDV biology and its applications in research.
Methods Used
- Infection of mammalian cells with a helper virus encoding T7 polymerase.
- Transfection of cells with plasmids containing minimal replication machinery of NDV.
- Co-cultivation of transfected mammalian cells with avian cells.
- Inoculation of embryonated chicken eggs with supernatant for virus amplification.
Main Results
- Successful rescue of recombinant NDV demonstrated through hemagglutination assay.
- Amplification of NDV in avian cells confirmed the effectiveness of the method.
- Procedure allows for the generation of NDV for further research and applications.
- Methodology provides a framework for future studies involving NDV.
Conclusions
- The described method effectively rescues NDV from cloned DNA.
- This technique can be utilized for vaccine development and therapeutic research.
- Further studies can build upon this methodology to explore NDV applications.
Frequently Asked Questions
What is Newcastle disease virus?
Newcastle disease virus (NDV) is a virus that primarily affects birds, causing significant disease in poultry.
How is recombinant NDV rescued?
Recombinant NDV is rescued by infecting mammalian cells with a helper virus and transfecting them with specific plasmids.
What is the purpose of using avian cells in this procedure?
Avian cells are used to amplify the newly generated variants of NDV, as they are the natural hosts for the virus.
What assay is used to confirm the presence of NDV?
A hemagglutination assay is used to demonstrate the presence of NDV in the harvested allantoic fluid.
Why is NDV being studied for vaccine development?
NDV has potential as a vector for vaccines due to its ability to induce strong immune responses.
What are the implications of this research?
This research may lead to new therapeutic strategies and improved vaccine formulations using NDV.
Executive Industry Relevance
Rescuing recombinant Newcastle disease virus from cDNA enables the generation of modified viral vectors for antigen delivery in vaccine and therapeutic development. This reverse genetics approach supports target validation by allowing precise genetic manipulation to interrogate viral pathogenesis and immune modulation. The method provides a scalable platform for producing recombinant viruses to assess antigen expression and immunogenicity in preclinical models.
Strategic Applications in Biopharma R&D
Early Discovery & Target Validation
- Scientific Value: Enables therapeutic hypothesis interrogation through precise genetic modification of NDV to study infection mechanisms and antigen presentation.
- Operational Value: Supports biological de-risking by generating isogenic viral variants to dissect host-pathogen interactions and vector safety profiles.
Screening & Assay Development
- Scientific Value: Produces standardized viral stocks for consistent antigen expression, enabling reliable evaluation of vaccine candidates in vitro and in vivo.
- Operational Value: Facilitates assay readiness through quantifiable outputs like hemagglutination titers, supporting reproducibility across discovery workflows.
Translational & Preclinical Research
- Scientific Value: Provides disease-relevant systems by rescuing viruses that replicate in avian cells and embryonated eggs, supporting translational continuity from discovery to preclinical evaluation.
- Operational Value: Enables risk-adjusted advancement decisions by allowing empirical assessment of vector stability, antigen expression levels, and immunogenic potential prior to GLP studies.
Pipeline & Workflow Integration
The rescue method fits within the early discovery continuum, enabling lead identification through vector optimization and supporting preclinical work by generating material for efficacy and safety assessment.
- Discovery Biology: Supports hypothesis testing by allowing insertion of antigen-encoding transcriptional units to evaluate immune responses and pathogenicity.
- Screening: Delivers assay-ready virus stocks with quantifiable hemagglutination activity, enabling standardized comparison of vector constructs.
- Analytics: Generates measurable outputs such as viral titers and hemagglutination units, facilitating data-driven decisions on vector performance.
- Translational Research: Connects discovery to preclinical validation through amplification in natural host systems, ensuring biological relevance of rescued virus.
- Enterprise Reuse: Establishes a reusable platform for generating diverse NDV-based vectors, reducing redundant optimization across projects.
Operational & Enterprise Impact
- Scientific Value: Enhances predictive confidence by enabling mechanistic de-risking of viral vectors through defined genetic modifications.
- Operational Value: Ensures standardization and reproducibility via a well-defined rescue protocol with quantifiable endpoints.
- Strategic Value: Improves go/no-go decisions by providing early insight into vector functionality and antigen delivery efficiency.
- Portfolio Impact: Supports risk-adjusted prioritization by enabling empirical evaluation of multiple vector designs before resource-intensive development.
Implementation Considerations
- Requires expertise in virology, molecular cloning, and cell culture techniques for successful transfection and virus rescue.
- Dependent on access to embryonated chicken eggs, avian fibroblast cultures, and biosafety-level-appropriate infrastructure for virus handling.
- Necessitates standardization of transfection efficiency and helper virus infection across mammalian and avian cell systems.
- Involves adaptation considerations when modifying the NDV genome, as insert size and transcriptional unit placement can affect virus rescue efficiency.
- Practical limitations include the need for biosafety containment and the dependency on embryonated egg systems for high-titer virus production.
Biopharma FAQs
Why does hemagglutination assay matter for confirming virus rescue?
The hemagglutination assay detects functional viral particles by measuring their ability to agglutinate turkey red blood cells, providing a quantitative readout of rescued virus presence in allantoic fluid. This assay serves as a critical quality control step to distinguish true rescue from background or incomplete replication.
How does co-culturing mammalian and avian cells support viral amplification?
Co-culturing allows the initial virus produced in mammalian cells to infect avian cells, which are the natural host of NDV, enabling a first round of amplification in a biologically relevant system. This step increases viral yield before egg inoculation, improving the efficiency of downstream propagation.
What role does the T7 polymerase helper virus play in the rescue process?
The MVA T7 helper virus provides T7 polymerase activity in mammalian cells, which drives transcription of the NDV genome from plasmids under the T7 promoter, enabling replication-competent virus generation. This system decouples viral transcription from dependence on endogenous polymerases, enhancing rescue efficiency.
Why is embryonated egg inoculation necessary for virus amplification?
Embryonated chicken eggs support high-titer growth of NDV due to their permissive allantoic cavity, which allows efficient viral replication and harvesting of clarified fluid. This step is essential for producing sufficient virus stock for downstream applications such as antigen expression studies or preclinical testing.
What statistical analysis is required to validate rescue success across replicates?
Rescue success is validated by comparing hemagglutination titers of experimental samples against negative and positive controls, requiring consistent signal above background in replicate assays. While not explicitly statistical, the assay depends on clear visual differentiation of agglutination patterns, supporting semi-quantitative assessment of rescue efficiency across conditions.
Chapters in this video
0:05
Title
1:37
Infection of Mammalian Cells with the Recombinant Modified Vaccinia Ankara Virus Expressing the Bacteriophage T7 RNA Polymerase (MVA-T7)
2:40
Transfection of Mammalian Cells
3:48
Co-culture of Mammalian Cells with Avian Cells
6:31
Harvest of Allentoic Fluid from Infected Chicken Embryonated Eggs
9:03
Results: Transfection and MVA-T7 Infection Efficiencies and Hemagglutination Assay
10:33
Conclusion
5:22
Infection of Chicken Embryonated Eggs
7:52
Hemagglutination (HA) Assay
